Q2053
HCPCSBrexucabtagene car pos t
Official HCPCS Level II long descriptor
Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
HCPCS Level II code Q2053 is maintained by CMS and is active in the current quarterly release.
Short descriptor
Brexucabtagene car pos t
Added to HCPCS: 2021-04-01
Nearby codes in Q2
- Q2038Fluzone vacc, 3 yrs & >, im
- Q2039Influenza virus vaccine, nos
- Q2041Axicabtagene ciloleucel car+
- Q2042Tisagenlecleucel car-pos t
- Q2043Sipuleucel-t auto cd54+
- Q2049Imported lipodox inj
- Q2050Doxorubicin inj 10mg
- Q2052Home ivig, services/supplies
- Q2054Lisocabtagene mara car pos t
- Q2055Idecabtagene vicleucel car
- Q2056Ciltacabtagene car-pos t
- Q2057Afamitresgene autoleucel
- Q2058Obecbtge autol up to 400 mil
Where this code sits
Krasyn Codes for Chrome
Review coding suggestions beside a validated web workflow. Private pilot.
Request pilot accessSource
HCPCS Level II July 2026 quarterly update. Centers for Medicare & Medicaid Services (CMS), “July 2026 Alpha-Numeric HCPCS File” (HCPC2026_JUL_ANWEB_06172026.txt). Download the original file from cms.gov. Public domain (US Government work). Descriptors, billable flags and instructional notes on this page are reproduced from that file without modification. Krasyn adds no clinical guidance.